Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease

2011/05/23 by Johannes‐Peter Stasch, Johannes-Peter Stasch, Pál Pacher +1 · 28 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Nitric Oxide and Endothelin Effects #Pulmonary Hypertension Research and Treatments #Adenosine and Purinergic Signaling

paper · pdf · doi:10.1161/circulationaha.110.981738

Cited by

• Discovery of the first isoform-specific sGC activator: Selective activation of GC-1 by runcaciguat
• Soluble GC stimulators and activators: Past, present and future
• International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases
• Reactive oxygen and nitrogen species in pulmonary hypertension. [europepmc]
• Genome-wide association study in Han Chinese identifies four new susceptibility loci for coronary artery disease. [europepmc]
• Nitric oxide-induced conformational changes in soluble guanylate cyclase. [europepmc]
• Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy. [europepmc]
• Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. [europepmc]
• The molecular targets of approved treatments for pulmonary arterial hypertension. [europepmc]
• Metabolic Profiling of Right Ventricular-Pulmonary Vascular Function Reveals Circulating Biomarkers of Pulmonary Hypertension. [europepmc]
• Regulation of soluble guanylyl cyclase redox state by hydrogen sulfide. [europepmc]
• Functional Characterization of the GUCY1A3 Coronary Artery Disease Risk Locus. [europepmc]
• Cytochrome b5 Reductase 3 Modulates Soluble Guanylate Cyclase Redox State and cGMP Signaling. [europepmc]
• RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. [europepmc]
• Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat. [europepmc]
• Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets. [europepmc]
• Redox control of vascular smooth muscle cell function and plasticity. [europepmc]
• Physiological activation and deactivation of soluble guanylate cyclase. [europepmc]
• Inflammatory Mediators Drive Adverse Right Ventricular Remodeling and Dysfunction and Serve as Potential Biomarkers. [europepmc]
• Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation [europepmc]
• Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. [europepmc]
• Allosteric activation of the nitric oxide receptor soluble guanylate cyclase mapped by cryo-electron microscopy. [europepmc]
• Pulmonary vasodilation in acute pulmonary embolism - a systematic review. [europepmc]
• GAPDH delivers heme to soluble guanylyl cyclase. [europepmc]
• The molecular mechanisms associated with the physiological responses to inflammation and oxidative stress in cardiovascular diseases. [europepmc]
• Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. [europepmc]
• Towards precision medicine in heart failure. [europepmc]
• Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial. [europepmc]